Malignant Lymphoma Small Lymphocytic — Patent Landscape
3
Approved drugs
490
Active US patents
46/100
Avg vulnerability
$5.8B
Annual revenue covered
Originators in Malignant Lymphoma Small Lymphocytic
Cliff calendar — next 15 years
70
26
87
27
7
28
2
29
3
30
123
31
14
32
96
33
30
34
21
35
36
36
1
39
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Imbruvica
ibrutinib
|
AbbVie | 448 | 43 | $3.2B | 2026-12-28 |
|
Venclexta
venetoclax
|
AbbVie | 30 | 47 | $2.6B | 2030-05-26 |
|
Copiktra
DUVELISIB
|
Secura | 12 | 47 | — | 2029-01-05 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8703780 | Imbruvica | method of use | 76 | 2026-12-28 |
| 8952015 | Imbruvica | method of use | 76 | 2026-12-28 |
| 8476284 | Imbruvica | method of use | 76 | 2026-12-28 |
| 8563563 | Imbruvica | method of use | 76 | 2027-04-26 |
| 9216982 | Copiktra | method of use | 75 | 2029-01-05 |
| 9216982 | Copiktra | method of use | 75 | 2029-01-05 |
| 12213983 | Copiktra | method of use | 75 | 2035-04-26 |
| 12213983 | Copiktra | method of use | 75 | 2035-04-26 |
| 8497277 | Imbruvica | method of use | 71 | 2026-12-28 |
| 11413282 | Venclexta | method of use | 70 | 2033-09-06 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 9296753 | Imbruvica | composition of matter | 0 | 2033-10-30 |
| 9296753 | Imbruvica | composition of matter | 0 | 2033-10-30 |
| 9296753 | Imbruvica | composition of matter | 0 | 2033-10-30 |
| 9296753 | Imbruvica | composition of matter | 0 | 2033-10-30 |
| 9296753 | Imbruvica | composition of matter | 0 | 2033-10-30 |
| 9296753 | Imbruvica | composition of matter | 0 | 2033-10-30 |
| 9296753 | Imbruvica | composition of matter | 0 | 2033-10-30 |
| 10125140 | Imbruvica | composition of matter | 0 | 2033-06-03 |
| 10106548 | Imbruvica | composition of matter | 0 | 2033-06-03 |
| 10106548 | Imbruvica | composition of matter | 0 | 2033-06-03 |
Related
- Malignant Lymphoma Small Lymphocytic — full disease profile
- AI Patent Landscape Report — type "malignant lymphoma small lymphocytic" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner